Ralf Barschow, chief executive officer of SomnoMed said, “We are pleased to see the US market gaining speed this rapidly. There is a huge untapped market in North America. By signing licensing agreements and distribution deals, we want to position the SomnoMed MAS as the best alternative to CPAP* for the treatment of sleep apnea and snoring.”
“We have a rigorous expansion strategy in place. With the appointment of key personnel and the signing of distribution agreements with market leaders around the world, we are confident that revenues will grow at a terrific rate for the coming quarters.”
SomnoMed had a total of $5.8 million in cash available at the end of March 2008. The Company has a strong balance sheet with no interest bearing liabilities
SOM Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)